Scott+Scott, Attorneys at Law, LLP Announces Investigation of Cellular Biomedicine Group Inc.
April 07 2015 - 3:11PM
Business Wire
Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national
shareholder and consumer rights litigation firm, announces the
commencement of an investigation into Cellular Biomedicine Group
Inc. (NASDAQ:CBMG) (“CBMG”) related to potential violations of
federal securities laws. If you are a CBMG shareholder, you are
encouraged to contact Scott+Scott for additional information.
CBMG (NASDAQ:CBMG) is a biomedicine company that develops
treatments for cancerous and degenerative diseases in Greater
China. CBMG focuses on developing and marketing cell-based
therapies to treat serious chronic and degenerative diseases.
On April 7, 2015, Seeking Alpha published a report on CBMG,
which asserts that: (i) CBMG has achieved an unsustainable
valuation with paid stock promotion; (ii) CBMG’s “CAR-T” technology
has experienced patient deaths and is worthless; (iii) CBMG’s
founders face multiple allegations of dishonesty and are
responsible for an alleged illegal offshore stem cell clinic; and
(iv) CBMG has multiple accounting and financial integrity issues.
On this news, shares of CBMG fell sharply during intraday trading
on April 7, 2015.
What You Can Do
If you are a CBMG shareholder and you wish to discuss this
investigation, or have questions about this notice or your legal
rights, please contact attorney Joseph Halloran at (800) 404-7770
or (646) 582-0121 or at or jhalloran@scott-scott.com.
About Scott+Scott, Attorneys at Law, LLP
Scott+Scott has significant experience in prosecuting major
securities, antitrust, and employee retirement plan actions
throughout the United States. The firm represents pension funds,
foundations, individuals, and other entities worldwide.
Scott+Scott, Attorneys at Law, LLPJoseph V. Halloran,
646-582-0121jhalloran@scott-scott.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024